Report Overview

The UK Wilson Disease Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The Wilson disease (WD), also known as hepatolenticular degeneration, and progressive lenticular degeneration, is a rare genetic disorder of copper metabolism characterized by excess copper stored in various body tissues, particularly the liver, brain, and corneas of the eyes. The disease is progressive and if left untreated, may cause liver (hepatic) failure, hemolytic crisis, central nervous system dysfunction, and death. It is caused by a mutation of the ATP7B gene and is inherited in an autosomal recessive manner. Early diagnosis and treatment may prevent serious long-term disability and life-threatening complications. Treatment is aimed at reducing the amount of copper accumulated in the body by chelation therapy and maintaining normal copper levels thereafter.

Wilson disease typically appears in people under 40 years old. Without treatment, life expectancy is estimated to be 40 years, but with prompt and efficient treatment, patients may have a normal lifespan. It is estimated that 1 in 30,000 people are affected by WD in the UK. Approximately one in 90 people may be carriers of the disease gene. Wilson disease is a rare disorder that affects males and females in equal numbers. The disease is found in all races and ethnic groups.

NCARDS is part of Public Health England, which is an executive agency of the Department of Health and Social Care. The Wilsons Disease Support Group (WDSG-UK), who provide crucial support to WD patients and their families, have been instrumental in spreading the word about NCARDRS to their members and giving us a forum to share our findings with them. We also actively engage with clinicians looking after people with WD, as part of the Wilsons Disease Special Interest Group (WDSIG).



Market Growth Drivers

The Wilsons disease Treatment market is primarily driven by the financial incentives and overall rewards for the successful development of drugs for the treatment and diagnosis of rare diseases and conditions. Moreover, the increasing awareness regarding Wilsons disease by various organizations and associations and its symptoms along with the growing population all over the world is expected to fuel the treatment market. For instance, the Wilsons Disease Association, a volunteer organization strives to promote the latest information about Wilsons disease and support research and clinical investigation for the disease.

However, technological advancement in treatment and diagnosis and rising genetic inherited disorders also boost up market growth. Moreover, increasing demand for treatment and rising patient awareness about different treatment options, increasing medical tourism, and rising investment by market players also generate market opportunities.

Market Restraints

However, the high initial investments resulting in higher per-patient treatment cost, adverse effects related to the treatment, and lower treatment rates may hamper the market over the forecast period.